Study Complete
Sponsor ID
20101123
Assessment of Quality of Life in Patients with Symptomatic Chemotherapy-induced Anaemia
Study Details
This is a multicenter, international, prospective, observational study of patients who are receiving systemic chemotherapy for solid tumour cancers (breast, colorectal, ovarian, prostate, lung, bladder, endometrial, renal, pancreatic, esophageal or gastric) and who are receiving darbepoetin alfa (Aranesp®) or other erythropoiesis-stimulating agent (ESA) to treat symptomatic anaemia.
Quality of Life will be assessed electronically with the aim of estimating improvement in quality of life for those patients receiving darbepoetin alfa (Aranesp®) who also have an increase in haemoglobin (Hb) of ≥1 g/dL
Protocol Summary
Primary Outcome Measures
Proportion of subjects receiving darbepoetin alfa with improvement in Patient Perceived Fatigue (PPF) and increase in Hb >=1 g/dL
Timeframe: From Baseline to Week 9
Secondary Outcome Measures
Proportion of subjects by tumour type with improvement in Patient Perceived Fatigue (PPF) and increase in Hb >=1 g/dL
Timeframe: From Baseline to Week 9
Study Documents
Study Synopsis
Available Language(s): English
Locations
Location
Research Site
St Poelten, Austria, 3100
Status
Completed
Location
Research Site
Innsbruck, Austria, 6020
Status
Completed
Location
Research Site
Gilly, Belgium, 6060
Status
Completed
Location
Research Site
Oostende, Belgium, 8400
Status
Completed
Location
Research Site
Mechelen, Belgium, 2800
Status
Completed
Location
Research Site
Verviers, Belgium, 4800
Status
Completed
Showing {first} - {last} of {total} Results